• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Monday, January 30, 2023
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Targeted test for antibiotic resistance in clinical Enterobacter species

Bioengineer by Bioengineer
January 23, 2023
in Health
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

The currently used microbiological tests for colistin resistance and other antibiotic resistances did not allow accurate conclusions regarding the spread of resistance in different Enterobacter species. This was partly because the taxonomic classification of clinical Enterobacter isolates was imprecise, and partly because the error rate in determining resistance was high. The large-scale DZIF study has now achieved a breakthrough and clarified the relationships between the numerous Enterobacter species as well as optimised resistance testing. To this end, researchers at the Institute of Medical Microbiology of Justus Liebig University Giessen (Deep-iAMR project), together with DZIF scientists at the Research Center Borstel Leibniz Lung Center, analysed Enterobacter isolates collected at German university hospitals over a period of three years.

Illustration of Enterobacteriacea

Credit: cdc/ Illustrator: Stephanie Russow

The currently used microbiological tests for colistin resistance and other antibiotic resistances did not allow accurate conclusions regarding the spread of resistance in different Enterobacter species. This was partly because the taxonomic classification of clinical Enterobacter isolates was imprecise, and partly because the error rate in determining resistance was high. The large-scale DZIF study has now achieved a breakthrough and clarified the relationships between the numerous Enterobacter species as well as optimised resistance testing. To this end, researchers at the Institute of Medical Microbiology of Justus Liebig University Giessen (Deep-iAMR project), together with DZIF scientists at the Research Center Borstel Leibniz Lung Center, analysed Enterobacter isolates collected at German university hospitals over a period of three years.

Using genome-based taxonomic studies, Enterobacter xiangfangensis was found to be the most frequently occurring species in German hospitals: From a data pool of over 3246 isolates worldwide—representing a collection from over twenty years—this species accounted for 68.7 percent of all Enterobacter detected.

Determination of antibiotic resistance profiles using phenotypic assays recommended by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) yielded mixed results with regard to colistin resistance.

“It turned out that many isolates were either not or barely resistant in these tests, even though the bacteria carried all the genes necessary for the expression of colistin resistance,” explains the study’s first author, Dr. Swapnil Doijad, of Friedrich Schiller University, Jena, Germany. A result that raised questions. The researchers obtained an initial answer by further investigating the isolates in which resistance was not clearly detectable using mass spectrometry.

“Depending on the particular Enterobacter species, we detected low levels of modified lipid A, the anchor structure of lipopolysaccharides (LPS)—a crucial component of the bacterial membrane and required for colistin resistance—even from bacteria grown in colistin-free medium,” comments the co-first author of the study, Dr. Nicolas Gisch of the Research Center Borstel Leibniz Lung Center. “These modifications of lipid A appear to be dependent on the bacterial species and are inherent, meaning their expression is embedded in a more complex regulation and not alone triggered by colistin,” he adds.

“The result suggests that there is species-dependent variation in the heteroresistance seen in Enterobacter: In routine test systems, the bacteria are sometimes resistant, sometimes not,” explains Dr. Can Imirzalioglu, co-author of the study and Acting Director for Clinical Microbiology and Diagnostics at the Institute of Medical Microbiology of Justus Liebig University Giessen.

Using further sophisticated methods, the authors were able to elucidate the phenomenon of heteroresistance in the genus Enterobacter. “Our analyses revealed that these bacteria have a sensor on their surface that responds to the pH value, i.e., the acidity in the environment, and regulates accordingly, either up or down, the genes required for the expression of colistin resistance,” explains Prof. Trinad Chakraborty, senior author and former director of the Institute of Medical Microbiology at Justus Liebig University Giessen. Genetic variations and interactions in this sensing pathway for environmental pH led to species-dependent differences regarding the extent of colistin resistance in the various Enterobacter species in conventional test systems.

Based on these findings, the researchers developed a simple new assay that eliminates heteroresistance effects and allows unambiguous and reliable determination of the true levels of colistin resistance for any isolate. The assay will avoid therapeutic failures when recommending the antibiotic, thereby paving the way for a targeted and economical treatment of Enterobacter species with this reserve antibiotic worldwide. A result that has come about not least through translational collaborations within the DZIF.



Journal

Nature Communications

DOI

10.1038/s41467-022-35717-0

Method of Research

Experimental study

Subject of Research

Human tissue samples

Article Title

Resolving colistin resistance and heteroresistance in Enterobacter species

Article Publication Date

10-Jan-2023

Share12Tweet8Share2ShareShareShare2

Related Posts

The two strategies that mutant measles viruses use to infect the brain

Measles virus ‘cooperates’ with itself to cause fatal encephalitis

January 27, 2023
Ólafsdóttir & Lind

Testing a immunological drug as a new treatment for early type 1 diabetes

January 27, 2023

Study shows FDA-approved TB regimen may not work against the deadliest form of TB due to multidrug-resistant strains

January 27, 2023

Non-invasive neurotechnology reduces symptoms of insomnia and improves autonomic nervous system function

January 27, 2023

POPULAR NEWS

  • Jean du Terrail, Senior Machine Learning Scientist at Owkin

    Nature Medicine publishes breakthrough Owkin research on the first ever use of federated learning to train deep learning models on multiple hospitals’ histopathology data

    64 shares
    Share 26 Tweet 16
  • First made-in-Singapore antibody-drug conjugate (ADC) approved to enter clinical trials

    58 shares
    Share 23 Tweet 15
  • Metal-free batteries raise hope for more sustainable and economical grids

    41 shares
    Share 16 Tweet 10
  • One-pot reaction creates versatile building block for bioactive molecules

    37 shares
    Share 15 Tweet 9

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

A fairy-like robot flies by the power of wind and light

UK’s Overseas Territories at ongoing risk from wide range of invasive species

World-first guidelines created to help prevent heart complications in children during cancer treatment

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 43 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In